1. Hong Kong Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H

Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H

HHKEX:8329
0.09
HKD
+0.00
(-4.08%)
239.95MMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.36
0.39
0.43
0.45
0.47
0.52
0.64
0.61
0.5
0.59
0.63
0.62
0.58
- -
Basic EPS, GAAP
0.02
0.02
0.01
0.04
0.03
0.03
0.04
0.02
0.02
0.03
0.01
0.01
-0.02
- -
Free Cash Flow per Basic Share
-0.02
0.01
0.02
0.04
0.02
- -
0.02
0.03
-0.05
0.02
0.02
- -
0.07
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.15
- -
Book Value per Share
0.28
0.3
0.32
0.36
0.39
0.42
0.45
0.47
0.49
0.53
0.54
0.56
0.39
0.56
Tangible Book Value per Share
0.2
0.22
0.25
0.29
0.32
0.32
0.39
0.42
0.37
0.4
0.42
0.44
0.31
0.45
Basic Weighted Avg Shares
1,678
1,678
1,678
1,678
1,678
1,678
1,678
1,678
1,678
1,678
1,678
1,678
1,678
1,678
Sales/Revenue/Turnover
612
648
721
759
790
867
1,081
1,031
839
987
1,065
1,042
972
- -
Operating Margin (%)
7.83
10.43
7
11.9
8.41
6.88
6.69
4.16
3.13
7.49
1.48
2.7
-4.34
- -
Depreciation Expense
22
23
23
20
19
20
24
26
30
36
34
35
33
- -
Net Income, GAAP
36
33
21
63
50
48
60
37
36
54
24
25
-41
- -
Effective Tax Rate (%)
- -
26.39
31.97
19.69
21.19
24.51
19.55
22.84
12.28
22.41
52.64
53.57
- -
- -
Profit Margin (%)
5.86
5.12
2.92
8.26
6.36
5.55
5.53
3.55
4.29
5.51
2.27
2.4
-4.19
- -
Working Capital
199
181
297
366
471
512
562
597
404
482
554
469
328
600
LT Debt
- -
- -
- -
- -
- -
- -
3
- -
1
4
4
5
3
8
Total Equity
561
600
632
700
750
799
860
896
944
1,005
1,016
1,026
704
1,057
Return on Invested Capital (%)
- -
7.6
5.18
9.64
7.15
6.47
7.46
4.33
3.95
6.54
1.58
1.47
- -
- -
Return on Capital (%)
- -
4.39
2.41
7.19
5.96
5.82
6.68
3.88
4.26
4.68
3.3
3.45
- -
- -
Return on Common Equity (%)
7.81
6.73
4.02
11.03
8.04
7.14
8.21
4.72
4.43
6.34
2.69
2.72
-5.15
- -

Capital Structure

CNY

•

in mil. unless spec.
Sep'23
Dec'23
Jun'24
ST Debt
- -
86
86
LT Borrowings
- -
2
6
LT Finance Leases
- -
1
3
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,678
1,678
1,678
Market Capitalization
257
250
223

Working Capital

CNY

•

in mil. unless spec.
Sep'23
Dec'23
Jun'24
Total Current Assets
- -
921
931
Cash, Cash Equivalents & STI
- -
382
392
Accounts Receivable, Net
- -
174
179
Inventories
- -
205
201
Total Current Liabilities
- -
366
331
Payables & Accruals
- -
- -
- -
ST Debt
- -
86
86
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
1.88%
-3.49%
-31.39%
Free Cash Flow
397.24%
1,015.23%
5,574.57%
Net Income, GAAP
-10.63%
-53.07%
-262.86%
Sales/Revenue/Turnover
3.71%
-0.4%
-6.69%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
1,042
2025
- -
- -
972
2026
- -
- -
- -

Semi-annual Earnings Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
0.01
2025
- -
- -
-0.02
2026
- -
- -
- -

Semi-annual Dividends Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
0.15
2026
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Feng Zhang
Full Time Employees
1,382
Sector
Health technology
Industry
Pharmaceuticals: major
Address
One Taikoo Place Hong Kong Hong Kong 518000
IPO Date
Sep 12, 2005
Website
interlong.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Shenzhen Neptunus Interlong Bio-technique Company Limited (8329.HK) engages in the research, development, manufacturing, and sale of medicines and medical devices in China. The company produces pharmaceuticals targeting oncology, cardiovascular, respiratory, digestive systems, and mental disorders; it also handles sales and distribution of medicines, healthcare food products, and medical devices through two main segments: manufacturing and selling of medicines/medical devices, and sales/distribution of medicines, healthcare products, and medical devices. Incorporated in 2002 and headquartered in Shenzhen with a listed office in Quarry Bay, Hong Kong, it primarily serves the domestic Chinese market and operates as a subsidiary of Shenzhen Neptunus Bio-engineering Company Limited. Recent developments include the announcement of a New Neptunus Group Sales Framework Agreement in late 2025 for ongoing transactions with related parties, alongside termination of a controlling shareholder's shareholding change in 2024 and release of 2024 annual results showing revenue of approximately HK$1.09 billion. The company maintains about 1,470 employees and focuses on biological technology R&D amid subdued growth and stock performance fluctuations in the pharmaceuticals sector.